{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:23:15Z","timestamp":1782476595741,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adverse events induced by crizotinib treatment for lung adenocarcinoma are increasingly reported, with nephritic inflammatory abscesses accounting for only 4% of documented cases. To date, no reports exist regarding aseptic inflammatory abscesses of the back. Consequently, these conditions are often misdiagnosed clinically as cancer metastases or other infections, leading to delays in patient treatment. We report a case of a 34-year-old female patient who developed aseptic inflammatory abscesses in the back and nephritic inflammatory abscesses induced by crizotinib treatment for ALK-rearranged lung adenocarcinoma. The inflammatory abscesses improved after discontinuation of crizotinib. Subsequently, the patient received reduced-dose crizotinib therapy, with follow-up showing reduced complications and satisfactory tumor control. This report aims to fill gaps in the understanding of crizotinib-related adverse events, thereby enhancing the accuracy of diagnosis and management of these adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 34-year-old female patient with stage IVB right lung adenocarcinoma, accompanied by lymph node, liver, and bone metastases, received crizotinib therapy. After two years of crizotinib treatment, imaging studies revealed an aseptic inflammatory abscess in the back and left kidney. The lesions in the back and left kidney continued to enlarge despite incision and drainage, and the back abscess underwent surgical excision one month later. Pathology revealed aseptic inflammatory reaction without cancer cells. However, the postoperative back incision healed poorly with persistent purulent discharge, and the nephritic abscess continued to enlarge. Subsequently, based on radiographic and pathological findings suggestive of crizotinib-related adverse effects, the dosage of crizotinib was discontinued. The aseptic inflammatory abscess on the back rapidly improved after crizotinib discontinuation. The nephritic abscess, however, developed infection post-discontinuation and significantly reduced in size following antimicrobial therapy and drainage. Subsequently, crizotinib dosage reduction was implemented based on genetic testing. During follow-up, the inflammatory abscess continued to shrink without compromising tumor control efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early identification and diagnosis of crizotinib-associated aseptic inflammatory abscesses are critical. During treatment, reducing crizotinib dosage does not lead to recurrence of lung cancer while minimizing complications. The case underscores the necessity of integrating imaging and pathological features in the diagnostic process, alongside the need for personalized adjustments and development of treatment plans tailored to each patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1812641","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:30:11Z","timestamp":1778733011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Aseptic inflammatory abscesses induced by crizotinib in a case report of ALK rearrangement lung adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongyin","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-19-0221","article-title":"Cancer progress and priorities: Lung cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.lungcan.2017.02.003","article-title":"Optimal management of ALK-positive NSCLC progressing on crizotinib","volume":"106","author":"Metro","year":"2017","journal-title":"Lung Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/annonc\/mdw304","article-title":"Crizotinib: From discovery to accelerated development to front-line treatment","volume":"29","author":"Blackhall","year":"2018","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-00859-6","article-title":"Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study","volume":"26","author":"Zhang","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70111","article-title":"Late-Onset Crizotinib-Associated Renal Cysts With Subsequent Regression Following Dose Reduction: A Case Report","volume":"16","author":"Yoon","year":"2025","journal-title":"Thorac Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03664-w","article-title":"Crizotinib: Aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC","volume":"147","author":"Weber","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.01.010","article-title":"Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics","volume":"106","author":"Halpenny","year":"2017","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000502664","article-title":"Crizotinib-Associated Renal Cysts in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients: A Single-Center Experience","volume":"104","author":"Eiamprapaporn","year":"2020","journal-title":"Urol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-017-0109-5","article-title":"Crizotinib associated renal cysts [CARCs]: Incidence and patterns of evolution","volume":"17","author":"Cameron","year":"2017","journal-title":"Cancer Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.11.001","article-title":"Development of complex hepatic cysts is a potential side effect of crizotinib","volume":"13","author":"Zaheed","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-025-04894-z","article-title":"Crizotinib-associated hepatic and renal cysts: a case report with MRI findings","volume":"50","author":"Yamamoto","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.437","article-title":"Complex renal cysts associated with crizotinib treatment","volume":"4","author":"Schnell","year":"2015","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4278","article-title":"Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature","volume":"9","author":"Wiest","year":"2021","journal-title":"Clin Case Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13000-024-01480-7","article-title":"Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: A case report and review of the literature","volume":"19","author":"Zhang","year":"2024","journal-title":"Diagn Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2016.04.010","article-title":"Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: A case report","volume":"11","author":"Chan","year":"2016","journal-title":"Radiol Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2020.03.011","article-title":"Development of complex renal cysts: A complication associated with crizotinib therapy","volume":"65","author":"Chen","year":"2020","journal-title":"Clin Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000326","article-title":"Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer","volume":"9","author":"Lin","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030160","article-title":"Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort","volume":"29","author":"Gibson","year":"2022","journal-title":"Curr Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105789","article-title":"A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abh1083","article-title":"Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis","volume":"16","author":"Neuwirt","year":"2023","journal-title":"Sci Signal"},{"key":"B22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s11658-023-00462-9","article-title":"The NLRP3 inflammasome: contributions to inflammation-related diseases","volume":"28","author":"Chen","year":"2023","journal-title":"Cell Mol Biol Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1257017","article-title":"Spoilt for choice: Different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer","volume":"14","author":"Heine","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1812641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:30:16Z","timestamp":1778733016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1812641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1812641"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1812641","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1812641"}}